College of Food Science and Engineering, Ocean University of China, 5 Yushan Road, Qingdao 266003, P. R. China.
Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore,, 1E Kent Ridge Road, Singapore 119228, Singapore.
Sci Adv. 2023 Apr 14;9(15):eade5041. doi: 10.1126/sciadv.ade5041. Epub 2023 Apr 12.
Milk-derived extracellular vesicles (mEVs) have been proposed as a potential nanomedicine for intestinal disorders; however, their impact on intestinal barrier integrity in gut inflammation and associated metabolic diseases has not been explored yet. Here, mEVs derived from bovine and human breast milk exert similar protective effects on epithelial tight junction functionality in vitro, survive harsh gastrointestinal conditions ex vivo, and reach the colon in vivo. Oral administration of mEVs restores gut barrier integrity at multiple levels, including mucus, epithelial, and immune barriers, and prevents endotoxin translocation into the liver in chemical-induced experimental colitis and diet-induced nonalcoholic steatohepatitis (NASH), thereby alleviating gut disorders, their associated liver inflammation, and NASH. Oral administration of mEVs has potential in the treatment of gut inflammation and gut-liver axis-associated metabolic diseases via protection of intestinal barrier integrity.
乳源细胞外囊泡（mEVs）被提议作为一种治疗肠道疾病的潜在纳米药物；然而，它们对肠道炎症和相关代谢疾病中肠道屏障完整性的影响尚未被探索。在这里，来源于牛乳和人乳的 mEVs 在体外对上皮紧密连接功能具有相似的保护作用，在体外能耐受恶劣的胃肠道条件，并且能在体内到达结肠。mEVs 的口服给药在多个水平上恢复肠道屏障的完整性，包括黏液、上皮和免疫屏障，并防止化学诱导的实验性结肠炎和饮食诱导的非酒精性脂肪性肝炎（NASH）中的内毒素易位到肝脏，从而缓解肠道疾病及其相关的肝脏炎症和 NASH。通过保护肠道屏障完整性，mEVs 的口服给药在治疗肠道炎症和肠道-肝脏轴相关代谢疾病方面具有潜力。
